Centurylink Investment Management Company Has Decreased Pfizer (PFE) Stake By $520,920; Novavax (NVAX)’s Sentiment Is 1.37

Pfizer Inc. (NYSE:PFE) Logo

Centurylink Investment Management Company decreased Pfizer Inc (PFE) stake by 13.3% reported in 2017Q4 SEC filing. Centurylink Investment Management Company sold 14,470 shares as Pfizer Inc (PFE)’s stock declined 3.13%. The Centurylink Investment Management Company holds 94,300 shares with $3.42 million value, down from 108,770 last quarter. Pfizer Inc now has $213.85B valuation. The stock increased 1.38% or $0.49 during the last trading session, reaching $35.95. About 19.88M shares traded. Pfizer Inc. (NYSE:PFE) has risen 2.43% since April 11, 2017 and is uptrending. It has underperformed by 9.12% the S&P500.

Novavax Inc (NVAX) investors sentiment increased to 1.37 in Q4 2017. It’s up 0.11, from 1.26 in 2017Q3. The ratio has improved, as 59 institutional investors increased and opened new positions, while 43 decreased and sold stock positions in Novavax Inc. The institutional investors in our database now possess: 124.34 million shares, up from 113.94 million shares in 2017Q3. Also, the number of institutional investors holding Novavax Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 30 Increased: 39 New Position: 20.

Among 22 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 12 Hold. Therefore 41% are positive. Pfizer has $54.0 highest and $33.0 lowest target. $39.80’s average target is 10.71% above currents $35.95 stock price. Pfizer had 76 analyst reports since July 29, 2015 according to SRatingsIntel. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) rating on Thursday, September 14. Piper Jaffray has “Buy” rating and $54.0 target. The rating was maintained by BMO Capital Markets with “Hold” on Monday, June 12. Cowen & Co maintained it with “Buy” rating and $4300 target in Monday, July 10 report. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by BMO Capital Markets on Tuesday, August 1. The stock of Pfizer Inc. (NYSE:PFE) has “Outperform” rating given on Thursday, October 19 by BMO Capital Markets. The rating was maintained by Cowen & Co on Monday, August 14 with “Buy”. The firm has “Outperform” rating by Credit Suisse given on Monday, May 9. The rating was maintained by Piper Jaffray on Saturday, September 5 with “Overweight”. Suntrust Robinson upgraded Pfizer Inc. (NYSE:PFE) on Wednesday, November 25 to “Neutral” rating. Jefferies maintained Pfizer Inc. (NYSE:PFE) on Wednesday, August 16 with “Hold” rating.

Since December 15, 2017, it had 0 insider buys, and 12 sales for $12.99 million activity. Dolsten Mikael also sold $501,398 worth of Pfizer Inc. (NYSE:PFE) on Friday, March 2. 1,758 shares valued at $64,679 were sold by CORNWELL W DON on Monday, February 26. MACKENZIE ALEXANDER R had sold 6,750 shares worth $249,750. $986,292 worth of Pfizer Inc. (NYSE:PFE) was sold by HILL CHARLES H. SUSMAN SALLY had sold 33,368 shares worth $1.24 million. LUND-JURGENSEN KIRSTEN had sold 9,510 shares worth $353,677 on Saturday, February 24. JOHNSON RADY A sold $296,560 worth of Pfizer Inc. (NYSE:PFE) on Friday, December 15.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on May, 1. They expect $0.73 EPS, up 5.80% or $0.04 from last year’s $0.69 per share. PFE’s profit will be $4.34 billion for 12.31 P/E if the $0.73 EPS becomes a reality. After $0.62 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts 17.74% EPS growth.

Investors sentiment increased to 1.06 in Q4 2017. Its up 0.10, from 0.96 in 2017Q3. It improved, as 51 investors sold PFE shares while 675 reduced holdings. 134 funds opened positions while 632 raised stakes. 4.07 billion shares or 0.28% more from 4.06 billion shares in 2017Q3 were reported. Intrust Retail Bank Na holds 0.72% or 67,158 shares in its portfolio. Dimensional Fund Advsr Lp reported 42.18 million shares. Hexavest Inc owns 2.86% invested in Pfizer Inc. (NYSE:PFE) for 6.93 million shares. Lincoln Cap Ltd Liability Corporation invested 0.23% of its portfolio in Pfizer Inc. (NYSE:PFE). Canada Pension Plan Invest Board holds 0.77% of its portfolio in Pfizer Inc. (NYSE:PFE) for 11.29M shares. Summit Fincl Wealth Advsrs Lc has invested 1.07% in Pfizer Inc. (NYSE:PFE). 266 were accumulated by Thomas J Herzfeld Advsrs Inc. Holderness Invests Commerce reported 70,593 shares. Alps Inc holds 1.39M shares. Lowe Brockenbrough Incorporated reported 18,228 shares or 0.09% of all its holdings. Schmidt P J Invest Mgmt, a Wisconsin-based fund reported 13,733 shares. Fort Washington Investment Advsr Oh holds 340,179 shares or 0.12% of its portfolio. North Amer reported 177,997 shares. Fagan Associate owns 36,813 shares. Btim Corporation invested in 93,792 shares or 0.05% of the stock.

The stock increased 3.96% or $0.08 during the last trading session, reaching $2.1. About 4.38 million shares traded. Novavax, Inc. (NVAX) has risen 53.85% since April 11, 2017 and is uptrending. It has outperformed by 42.30% the S&P500.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $678.78 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

Ratings analysis reveals 14% of Novavax’s analysts are positive. Out of 7 Wall Street analysts rating Novavax, 1 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $1.5 while the high is $12.0. The stock’s average target of $5.17 is 146.19% above today’s ($2.1) share price. NVAX was included in 7 notes of analysts from September 16, 2016. The company was downgraded on Friday, September 16 by Citigroup. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Neutral” rating by Piper Jaffray on Friday, September 16. Wedbush downgraded the stock to “Neutral” rating in Friday, September 16 report. The stock of Novavax, Inc. (NASDAQ:NVAX) has “Outperform” rating given on Friday, September 16 by FBR Capital. The firm has “Neutral” rating given on Tuesday, September 20 by Chardan Capital Markets. The firm has “Neutral” rating by JP Morgan given on Friday, September 16. The rating was downgraded by Ladenburg Thalmann to “Neutral” on Friday, September 16.

Since January 1, 0001, it had 1 insider purchase, and 0 sales for $11,250 activity.

Novavax, Inc. (NASDAQ:NVAX) Institutional Positions Chart